SESSION R.A. II (President and CEO) purchased 0.5% of their position (42.52K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market purchase worth $529.1K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 12/8/2021ACC: 0001209191-21-068510
DirectorOfficer10% Owner· President and CEO
Since Sep 2020
+42.52K
Net shares
Net buyer
$529.1K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
42.52K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+16.51K
Price / share
$12.12
Trade value
$200.10K
% of position
0.2%
11/23/2021
9.15M→9.16M
Common Stock
Direct
Shares
+26.01K
Price / share
$12.65
Trade value
$329K
% of position
0.3%
11/23/2021
9.16M→9.19M
Total
Net shares
+42.52K
Net value
$529.10K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/23/2021 | P · Purchase | +16.51K | $12.12 | $200.10K | 0.2% | 9.15M | 9.16M |
| Common Stock Direct | 11/23/2021 | P · Purchase | +26.01K | $12.65 | $329K | 0.3% | 9.16M | 9.19M |
| Total | +42.52K | $529.10K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned141.09K
Common Stock
IndirectShares owned141.09K
Total
282.18K indirect282.18K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 141.09K | Indirect |
| Common Stock | 141.09K | Indirect |
| Total | 282.18K | 282.18K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported